More articles from Volume 46, Issue 3, 2017
Randomization techniques in protocols for cluster randomized trials
Systematic review of factor validity of psychiatric scales in longitudinal studies
Comparison of clinical, biochemical and morphological parameters in patients with chronic hepatitis B
Impact of ocular comorbidities on visual function and quality of life in cataract and pseudophakic patients
Effects of different doses of zinc gluconate on antioxidative activity of metformin and glibenclamide on experimentally induced diabetes in rabbits
Cognitive functions of patients with epilepsy treated by topiramate
,
Nenad Milosevic
,
Boban Bisevac
,
Snezana Danic-Filipovic
,
Mirjana Dejanovic
,
Marko Miric
Jovana Milosevic
Abstract
Keywords
References
1.
Dooley J, Camfield P, Smith E. Topiramate in intractable childhood onset epilepsy: a cautionary note. Can J Neurol Sci. 1999;271–3.
2.
Crawford P. An audit of topiramate use in a general neurology clinic. Seizure. 1998;207–11.
3.
Jones M. Topiramate: safety and tolerability. Can J Neurol Sci. 1998;13–5.
4.
Bootsma H, Ricker L, Diepman L, Gehring J, Hulsman J, Lambrechts D. Long-term effects of levetiracetam and topiramate in clinical practice: A head-to-head comparison. Seizure. 2008;(1):19–26.
5.
Burton L, Harden C. Effect of topiramate on attention. Epilepsy Res. 1997;29–32.
6.
Mecarelli O, Piacenti A, Pulitano P, Vicenzini E, Rizzo C, Rinalduzzi S. Clinical and electroencephalographic effects of topiramate in patients with epilepsy and healthy volunteers. Clin Neuropharmacol. 2001;284–9.
7.
Milošević N. Analiza faktora rizika za pojavu kognitivnih neželjenih efekata topiramata u terapiji epilepsije. Magistarska teza. 2009;
8.
Stretton J, Thompson P. Frontal lobe function in temporal lobe epilepsy. Epilepsy Res. 2012;(1):1–13.
9.
Milošević N. Analiza faktora rizika za pojavu poremećaja egzekutivnih funkcija kod bolesnika sa temporalnom lobarnom epilepsijom. 2014;
10.
Reife R, Pledger G. Topiramate as adjunctive therapy in refractory partial epilepsy: pooled analysis of data from five doubleblind, placebo-controlled trials. Epilepsia. 1997;31–3.
11.
Lee S, Sziklas V, Andermann F, Farnham S, Risse G, Gustafson M. The Effects of Adjunctive Topiramate on Cognitive Function in Patients with Epilepsy Epilepsia. 2003;339.
12.
Thompson P, Baxendale S, Duncan J. Effects of topiramate on cognitive function. J Neurol Neurosurg Psychiatry. 2000;636–41.
13.
Martin R, Kuzniecky R, Ho S. Cognitive effects of topiramate, gabapentin, and lamotrigine in healthy young adults. Neurology. 1999;321–7.
14.
Meador K, Loring D, Vahle V, Ray P, Verz M, Fessler A. Gognitive and behavioral effects of lamotrigine and topiramate in healthy volunteers. Neurology. 2005;2108–14.
15.
Kockelmann E, Che E, Ch H. Cognitive profile of topiramate as compared with lamotrigine in epilepsy patients on antiepileptic drug polytherapy: relationships to blood serum levels and comedication. Epilepsy & Behavior. 2004;716–21.
16.
Blum D, Meador K, Biton V, Fakhoury T, Shneker B, Chung S. Cognitive effects of lamotrigine compared with topiramate in patients with epilepsy. Neurology. 2006;(3):400–6.
17.
Aldenkamp A, Baker G, Mulder O. A randomized observer-blind clinical study comparing the cognitive effects of topiramate versus valproate in a first-line add-on design. Epilepsia. 1998;188–9.
18.
Aldenkamp A, Baker G, Mulder O. A multicenter, randomized clinical study to evaluate the effect on cognitive function of topiramate compared with valproate as add-on therapy to carbamazepine in patients with partial-onset seizures. Epilepsia. 2000;1167–78.
19.
Meador K, Loring D, Hulihan J, Kamin M, Karim R. Differential cognitive and behavioral effects of topiramate and valproate. Neurology. 2003;(9):1483–8.
20.
Fritz N, Glogau S, Hoffmann J, Rademacher M. Elger CE and Helmstaedter C Efficacy and cognitive side effects of tiagabine and topiramate in patients with epilepsy. Epilepsy & Behavior. 2005;373–81.
21.
Meador K. Cognitive Effects of Levetiracetam versus Topiramate. Epilepsy Curr. 2008;64–5.
22.
Bootsma H, Aldenkamp A, Hulsman J, Lambrechts D, Leenen L, Majoie M. The Effect of Antiepileptic Drugs on Cognition: Patient Perceived Cognitive Problems of Topiramate versus Levetiracetam in Clinical Practice. Epilepsia. 2006;24–7.
23.
Gomer B, Wagner K, Frings L. The influence of antiepileptic drugs on cognition: a comparison of levetiracetam with topiramate. Epilepsy Behav. 2007;486–94.
24.
Ortinski P, Meador K. Cognitive side effects of antiepileptic drugs. Epilepsy & Behavior. 2004;60–5.
25.
Guberman A, Neto W, Gassmann-Mayer C. Low-dose topiramate in adults with treatment.resistant partial-onset seizures. Acta Neurol Scand. 2002;183–9.
26.
Baeta E, Santana I, Castro G, Goncalves S, Goncalves T, Carmo I. Cognitive effects of therapy with topiramate in patients with refractory partial epilepsy. Rev Neurol. 2002;(30):41.
27.
Edwards K, Potter D, Wu S. Topiramate in the prevenrtive treatment of episodic migraine: a combined analisys from pilot, double-blind, placebo-controlled triels. CNS Spectr. 2003;428–32.
28.
Bootsma H, Coolen F, Aldenkamp A. Topiramate in clinical practice: long-term experience in patients with refractory epilepsy referred to a tertiary epilepsy center. Epilepsy Behav. 2004;380–7.
29.
Milošević N, Sokić D, Ristić A. Depresija kao faktor rizika za razvoj kognitivnih neželjenih efekata topiramata u terapiji epilepsije. Praxis medica. 2009;65–8.
30.
Milošević N, Nenadović M, Šternić N. Uloga uzrasta na početku epilepsije u pojavi kognitivnih poremećaja nakon uvođenja topiramata. Praxis medica. 2012;
31.
Privitera M, Fincham R, Penry J. Topiramate placebo-controlled dose-ranging trial in refractory partial epilepsy using 600-, 800-, and 1000-mg daily dosages. Topiramate YE Study Group. Neurology. 1996;1678–83.
32.
Froscher W, Schier K, Hoffmann M, Meyer A, May T, Rambeck B. Topiramate: a prospective study on the relationship between concentration, dosage and adverse events in epileptic patients on combination therapy. Epileptic Disord. 2005;(3):237–48.
33.
Kwan P, Brodie M. Neuropsychological effects and antiepileptic drugs. Lancet. 2001;216–22.
34.
Binnie C. Cognitive impairment during epileptiform discharges: is it ever justifiable to treat the EEG? Lancet Neurol. 2003;725–30.
35.
Petroff O, Hyder F, Rothman D, Mattson R. Topiramate rapidly raises brain GABA in epilepsy patients. Epilepsia. 2001;543–8.
36.
Aldenkamp A, Baker G. A systematic review of the effects of lamotrigine on cognitive function and quality of life. Epilepsy Behav. 2001;85–91.
37.
Aldenkamp A, Bodde N. Behavior, cognition and epilepsy. Acta Neurol Scand Suppl. 2005;19–25.
38.
Stroop J. Studies of interference in serial verbal reaction. J Exp Psychol. 1935;643–62.
39.
Roberts G, Majoie H, Leenen L, Bootsma H, Kessels A, Aldenkamp A. Ketter’s hypothesis of the mood effects of antiepileptic drugs coupled to the mechanism of action of topiramate and levetiracetam. Epilepsy Behav. 2005;366–72.
40.
Milošević N, Sokić D, Ristić A. Odnos efikasnosti topiramata u kontroli epileptičkih napada i pojave kognitivnih neželjenih efekata. Praxis medica. 2010;(1–2):61–4.
41.
Majkowski J, Neto W, Wapenaar R, Van Oene J. Time course of adverse events in patients with localization-related epilepsy receiving topiramate added to carbamazepine. Epilepsia. 2005;648–53.
42.
Kellet M, Smith D, Stockton P, Chadwick D. Topiramate in clinical practice: first year’s postlicensing experience in a specialist epilepsy clinic. J Neurol Neurosurg Psychiatry. 1999;759–63.
43.
Lhatoo S, Wong I, Sander J. Prognostic factors affecting long-term retention of topiramate in patients with chronic epilepsy. Epilepsia. 2000;388–431.
44.
Marson A, Kadir Z, Hutton J. The new antiepileptic drugs:a systemic review of their efficacy and tolerability. Epilepsia. 1997;859–80.
45.
Nenad1ˑ2 CFOPWETBTM, Boban3 B, Snežana F, Danić1ˑ2 D, Mirjana1 M, Marko1.
Citation
Copyright
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Article metrics
Google scholar:
See link
The statements, opinions and data contained in the journal are solely those of the individual authors and contributors and not of the publisher and the editor(s). We stay neutral with regard to jurisdictional claims in published maps and institutional affiliations.
